214 related articles for article (PubMed ID: 16291292)
21. Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
Novick D; Ascher-Svanum H; Brugnoli R; Bertsch J; Hong J; Haro JM
J Nerv Ment Dis; 2012 Jul; 200(7):637-43. PubMed ID: 22759944
[TBL] [Abstract][Full Text] [Related]
22. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Meyer JM; Davis VG; McEvoy JP; Goff DC; Nasrallah HA; Davis SM; Daumit GL; Hsiao J; Swartz MS; Stroup TS; Lieberman JA
Schizophr Res; 2008 Aug; 103(1-3):104-9. PubMed ID: 18534821
[TBL] [Abstract][Full Text] [Related]
23. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
Perkins DO; Gu H; Weiden PJ; McEvoy JP; Hamer RM; Lieberman JA;
J Clin Psychiatry; 2008 Jan; 69(1):106-13. PubMed ID: 18312044
[TBL] [Abstract][Full Text] [Related]
24. The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
Berkowitz RL; Patel U; Ni Q; Parks JJ; Docherty JP
J Clin Psychiatry; 2012 Apr; 73(4):498-503. PubMed ID: 22226332
[TBL] [Abstract][Full Text] [Related]
25. Results of phase 3 of the CATIE schizophrenia trial.
Stroup TS; Lieberman JA; McEvoy JP; Davis SM; Swartz MS; Keefe RS; Miller AL; Rosenheck RA; Hsiao JK;
Schizophr Res; 2009 Jan; 107(1):1-12. PubMed ID: 19027269
[TBL] [Abstract][Full Text] [Related]
26. Antipsychotic drugs and schizophrenia.
Essock SM; Covell NH; Jackson CT
N Engl J Med; 2006 Jan; 354(3):298-300; author reply 298-300. PubMed ID: 16422020
[No Abstract] [Full Text] [Related]
27. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
[TBL] [Abstract][Full Text] [Related]
28. Novel antipsychotic use in schizophrenia.
J Clin Psychiatry; 2000 Mar; 61(3):223-32. PubMed ID: 10841660
[No Abstract] [Full Text] [Related]
29. Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists.
Bick P; Knoesen N; Castle D
Australas Psychiatry; 2007 Dec; 15(6):465-9. PubMed ID: 17999256
[TBL] [Abstract][Full Text] [Related]
30. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
31. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.
Jensen JB; Kumra S; Leitten W; Oberstar J; Anjum A; White T; Wozniak J; Lee SS; Schulz SC
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):317-26. PubMed ID: 18759641
[TBL] [Abstract][Full Text] [Related]
32. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression.
Galynker I; Khan A; Grebchenko Y; Ten A; Malaya L; Yanowitch P; Cohen LJ
J Clin Psychiatry; 2005 Apr; 66(4):544. PubMed ID: 15816805
[No Abstract] [Full Text] [Related]
33. Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?
Meltzer HY
Int J Neuropsychopharmacol; 2005 Jun; 8(2):153-6. PubMed ID: 15780147
[No Abstract] [Full Text] [Related]
34. [First episode psychoses: psychosocial, interpersonal and cognitive bases for a therapeutic approach].
Di Michele V; Mazza M; Pollice R; Bolino F; Giosuè P; Roncone R; Casacchia M
Clin Ter; 2007; 158(1):85-96. PubMed ID: 17405662
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of switching antipsychotic medications.
Essock SM; Covell NH; Davis SM; Stroup TS; Rosenheck RA; Lieberman JA
Am J Psychiatry; 2006 Dec; 163(12):2090-5. PubMed ID: 17151159
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of atypical antipsychotics in patients with Alzheimer's dementia. CATIE-AD-Study (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer's Disease)].
Förstl H
Internist (Berl); 2007 Jun; 48(6):642-4. PubMed ID: 17497111
[No Abstract] [Full Text] [Related]
37. Risperidone and clozapine for treatment-resistant schizophrenia.
Dunayevich E; Chatterjee A
Am J Psychiatry; 1999 Jul; 156(7):1127; author reply 1127-8. PubMed ID: 10401486
[No Abstract] [Full Text] [Related]
38. Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.
Hermes E; Rosenheck R
J Psychopharmacol; 2012 Sep; 26(9):1194-200. PubMed ID: 22516668
[TBL] [Abstract][Full Text] [Related]
39. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
Potkin SG; Gharabawi GM; Greenspan AJ; Mahmoud R; Kosik-Gonzalez C; Rupnow MF; Bossie CA; Davidson M; Burtea V; Zhu Y; Trivedi JK
Schizophr Res; 2006 Jul; 85(1-3):254-65. PubMed ID: 16797162
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
Suzuki T; Uchida H; Watanabe K; Nakajima S; Nomura K; Takeuchi H; Tanabe A; Yagi G; Kashima H
Hum Psychopharmacol; 2008 Aug; 23(6):455-63. PubMed ID: 18537222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
